Total Payments
$394,549
2024 Payments
$2,570
Companies
28
Transactions
417
Medicare Patients
733
Medicare Billing
$96,967
Payment Breakdown by Category
Other$183,799 (46.6%)
Consulting$131,071 (33.2%)
Travel$65,029 (16.5%)
Food & Beverage$13,397 (3.4%)
Research$1,189 (0.3%)
Education$65.31 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $173,054 | 60 | 43.9% |
| Consulting Fee | $131,071 | 44 | 33.2% |
| Travel and Lodging | $65,029 | 103 | 16.5% |
| Food and Beverage | $13,397 | 195 | 3.4% |
| Compensation for serving as faculty or as a speaker for a medical education program | $5,640 | 1 | 1.4% |
| Honoraria | $5,105 | 6 | 1.3% |
| Unspecified | $1,189 | 4 | 0.3% |
| Education | $65.31 | 4 | 0.0% |
Payments by Type
General
$393,361
413 transactions
Research
$1,189
4 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| GENZYME CORPORATION | $165,235 | 133 | $0 (2023) |
| Fisher & Paykel Healthcare Limited | $50,372 | 31 | $0 (2023) |
| Genentech USA, Inc. | $46,499 | 38 | $0 (2022) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $41,824 | 33 | $0 (2024) |
| United Therapeutics Corporation | $23,637 | 48 | $0 (2024) |
| Philips Electronics North America Corporation | $15,015 | 11 | $0 (2022) |
| GlaxoSmithKline, LLC. | $12,576 | 16 | $0 (2024) |
| Gilead Sciences, Inc. | $8,994 | 10 | $0 (2018) |
| Breas Medical, Inc. | $6,875 | 4 | $0 (2023) |
| Merck Sharp & Dohme LLC | $4,609 | 9 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $2,570 | 17 | Merck Sharp & Dohme LLC ($1,574) |
| 2023 | $47,303 | 39 | GENZYME CORPORATION ($21,127) |
| 2022 | $43,730 | 40 | GENZYME CORPORATION ($19,586) |
| 2021 | $16,764 | 22 | GENZYME CORPORATION ($5,717) |
| 2020 | $33,224 | 28 | GENZYME CORPORATION ($15,371) |
| 2019 | $138,358 | 113 | GENZYME CORPORATION ($78,603) |
| 2018 | $20,382 | 39 | Genentech USA, Inc. ($10,043) |
| 2017 | $92,217 | 119 | GENZYME CORPORATION ($24,830) |
All Payment Transactions
417 individual payment records from CMS Open Payments — Page 1 of 17
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/18/2024 | United Therapeutics Corporation | ORENITRAM (Drug), REMODULIN | Food and Beverage | In-kind items and services | $116.30 | General |
| Category: Pulmonary Arterial Hypertension | ||||||
| 10/08/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $311.18 | General |
| 10/08/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | OFEV (Drug) | Food and Beverage | In-kind items and services | $130.38 | General |
| Category: RESPIRATORY | ||||||
| 10/08/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $78.79 | General |
| 10/07/2024 | Merck Sharp & Dohme LLC | — | Food and Beverage | In-kind items and services | $30.70 | General |
| 05/23/2024 | GlaxoSmithKline, LLC. | NUCALA (Biological) | Food and Beverage | In-kind items and services | $31.64 | General |
| Category: IMMUNOLOGY | ||||||
| 05/21/2024 | Merck Sharp & Dohme LLC | — | Food and Beverage | In-kind items and services | $143.39 | General |
| 05/21/2024 | Merck Sharp & Dohme LLC | — | Food and Beverage | In-kind items and services | $125.00 | General |
| 04/08/2024 | Aero US Inc | AEROGEN SOLO NEBULIZER SYSTEM (Device), AEROGEN USB CONTROLLER SYSTEM, AEROGEN SOLO NEBULIZER SYSTEM | Food and Beverage | In-kind items and services | $30.64 | General |
| Category: RESPIRATORY | ||||||
| 04/03/2024 | Merck Sharp & Dohme LLC | — | Consulting Fee | Cash or cash equivalent | $1,275.00 | General |
| Category: CARDIOVASCULAR | ||||||
| 04/03/2024 | Actelion Pharmaceuticals US, Inc. | UPTRAVI (Drug) | Food and Beverage | In-kind items and services | $15.58 | General |
| Category: Cardiology | ||||||
| 02/15/2024 | Actelion Pharmaceuticals US, Inc. | — | Food and Beverage | In-kind items and services | $27.96 | General |
| 02/02/2024 | Sandoz Inc. | TREPROSTINIL (Drug) | Food and Beverage | In-kind items and services | $39.57 | General |
| Category: Pulmonary/Respiratory Diseases | ||||||
| 02/01/2024 | Sandoz Inc. | TREPROSTINIL (Drug) | Food and Beverage | In-kind items and services | $55.70 | General |
| Category: Pulmonary/Respiratory Diseases | ||||||
| 01/31/2024 | Actelion Pharmaceuticals US, Inc. | — | Food and Beverage | In-kind items and services | $141.68 | General |
| 01/20/2024 | Actelion Pharmaceuticals US, Inc. | UPTRAVI (Drug) | Food and Beverage | In-kind items and services | $5.70 | General |
| Category: Cardiology | ||||||
| 01/07/2024 | Actelion Pharmaceuticals US, Inc. | UPTRAVI (Drug) | Food and Beverage | In-kind items and services | $11.14 | General |
| Category: Cardiology | ||||||
| 12/05/2023 | GENZYME CORPORATION | LUMIZYME (Biological) | Consulting Fee | Cash or cash equivalent | $4,530.00 | General |
| Category: Genetic Disease | ||||||
| 12/05/2023 | GENZYME CORPORATION | LUMIZYME (Biological) | Travel and Lodging | In-kind items and services | $126.50 | General |
| Category: Genetic Disease | ||||||
| 12/05/2023 | GENZYME CORPORATION | LUMIZYME (Biological) | Food and Beverage | In-kind items and services | $69.99 | General |
| Category: Genetic Disease | ||||||
| 12/05/2023 | GENZYME CORPORATION | LUMIZYME (Biological) | Food and Beverage | In-kind items and services | $31.84 | General |
| Category: Genetic Disease | ||||||
| 11/17/2023 | Boehringer Ingelheim Pharmaceuticals, Inc. | — | Consulting Fee | Cash or cash equivalent | $6,093.75 | General |
| 11/05/2023 | Breas Medical, Inc. | Vivo 45 LS (Device) | Honoraria | Cash or cash equivalent | $250.00 | General |
| Category: Respiratory | ||||||
| 11/01/2023 | Breas Medical, Inc. | Vivo 45 LS (Device) | Consulting Fee | Cash or cash equivalent | $3,125.00 | General |
| Category: Respiratory | ||||||
| 10/30/2023 | Paratek Pharmaceuticals, Inc. | NUZYRA (Drug) | Education | In-kind items and services | $39.95 | General |
| Category: ANTIBIOTIC | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| An Extension Study to Assess the Safety, Tolerability, and Effectiveness of the Long-Term Use of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD) | Insmed, Inc. | $1,189 | 4 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 7 | 143 | 196 | $76,236 | $16,757 |
| 2022 | 4 | 114 | 160 | $64,541 | $15,223 |
| 2021 | 9 | 223 | 313 | $130,953 | $32,224 |
| 2020 | 10 | 253 | 383 | $128,870 | $32,764 |
Total Patients
733
Total Services
1,052
Medicare Billing
$96,967
Procedure Codes
30
All Medicare Procedures & Services
30 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 49 | 76 | $40,272 | $9,052 | 22.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 30 | 38 | $14,481 | $3,003 | 20.7% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 15 | 33 | $6,849 | $2,231 | 32.6% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2023 | 14 | 14 | $9,048 | $2,167 | 23.9% |
| 94727 | Test to determine lung volumes using gas dilution or washout | Facility | 2023 | 11 | 11 | $1,146 | $110.88 | 9.7% |
| 94729 | Test to examine how well the lungs exchange gases | Facility | 2023 | 13 | 13 | $2,425 | $97.37 | 4.0% |
| 94060 | Test to measure expiratory airflow and volume changes before and after medication administration | Facility | 2023 | 11 | 11 | $2,015 | $95.04 | 4.7% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 54 | 72 | $27,045 | $5,563 | 20.6% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 28 | 32 | $16,508 | $4,108 | 24.9% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 20 | 44 | $13,163 | $3,631 | 27.6% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2022 | 12 | 12 | $7,825 | $1,920 | 24.5% |
| 99291 | Critical care delivery critically ill or injured patient, first 30-74 minutes | Facility | 2021 | 26 | 46 | $42,090 | $8,699 | 20.7% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 54 | 77 | $27,566 | $6,151 | 22.3% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 34 | 57 | $19,551 | $5,095 | 26.1% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 28 | 39 | $18,720 | $4,853 | 25.9% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 13 | 13 | $8,671 | $2,253 | 26.0% |
| 99443 | Physician telephone patient service, 21-30 minutes of medical discussion | Facility | 2021 | 21 | 28 | $3,528 | $2,052 | 58.2% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Facility | 2021 | 11 | 11 | $7,491 | $1,752 | 23.4% |
| 99442 | Physician telephone patient service, 11-20 minutes of medical discussion | Facility | 2021 | 15 | 18 | $1,512 | $939.66 | 62.1% |
| 94618 | Test for exercise-induced lung stress | Facility | 2021 | 21 | 24 | $1,824 | $430.32 | 23.6% |
| 99291 | Critical care delivery critically ill or injured patient, first 30-74 minutes | Facility | 2020 | 22 | 53 | $48,495 | $10,193 | 21.0% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 29 | 66 | $22,638 | $6,012 | 26.6% |
| 99443 | Physician telephone patient service, 21-30 minutes of medical discussion | Facility | 2020 | 42 | 69 | $8,694 | $4,713 | 54.2% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 43 | 59 | $19,142 | $3,635 | 19.0% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Facility | 2020 | 23 | 26 | $10,646 | $2,106 | 19.8% |
About Dr. Nicholas Hill, MD
Dr. Nicholas Hill, MD is a Critical Care Medicine healthcare provider based in Boston, Massachusetts. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/02/2006. The National Provider Identifier (NPI) number assigned to this provider is 1558308874.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Nicholas Hill, MD has received a total of $394,549 in payments from pharmaceutical and medical device companies, with $2,570 received in 2024. These payments were reported across 417 transactions from 28 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($173,054).
As a Medicare-enrolled provider, Hill has provided services to 733 Medicare beneficiaries, totaling 1,052 services with total Medicare billing of $96,967. Data is available for 4 years (2020–2023), covering 30 distinct procedure/service records.
Ad
Practice Information
- Specialty Critical Care Medicine
- Other Specialties Pulmonary Disease, Pulmonary Disease
- Location Boston, MA
- Active Since 06/02/2006
- Last Updated 01/09/2017
- Taxonomy Code 207RC0200X
- Entity Type Individual
- NPI Number 1558308874
Products in Payments
- LUMIZYME (Drug) $101,428
- Obstructive Sleep Apnea Device or Hospital Respiratory Equipment (Device) $25,170
- LUMIZYME (Biological) $23,778
- NEXVIAZYME (Biological) $12,366
- FISHER & PAYKEL HEALTHCARE (Device) $11,816
- Esbriet (Biological) $7,786
- VIAGRA (Drug) $7,400
- Vivo 45 LS (Device) $6,875
- (2858) General Consulting (Device) $5,640
- TRELEGY ELLIPTA (Drug) $5,022
- ORENITRAM (Drug) $4,902
- (8362) US Enabling function (Device) $3,348
- InogenOne (Device) $2,700
- Non-Covered Product (Drug) $2,485
- (8599) Chief Medical Officer (Device) $2,350
- DISEASE STATE (Drug) $2,006
- INOGEN (Device) $1,350
- Trilogy 100 (Device) $1,148
- S&RC Und (Device) $1,052
- CardioMD (Device) $1,000
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Critical Care Medicine Doctors in Boston
Dr. Joseph Zibrak, Md, MD
Critical Care Medicine — Payments: $167,344
Critical Care Medicine $167,344
Dr. George Washko, Md, MD
Critical Care Medicine — Payments: $123,820
Critical Care Medicine $123,820
Dr. Charles Cote, Md, MD
Critical Care Medicine — Payments: $33,677
Critical Care Medicine $33,677
Lorenzo Berra, Md, MD
Critical Care Medicine — Payments: $31,520
Critical Care Medicine $31,520
Ronald Goldstein, M.d, M.D
Critical Care Medicine — Payments: $12,067
Critical Care Medicine $12,067
Dr. William Gormley, Md, MD
Critical Care Medicine — Payments: $11,878
Critical Care Medicine $11,878